Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) alongside an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transactions are expected to generate approximately $4 million in aggregate gross proceeds, subject to customary conditions, with closing anticipated on or about October 15, 2026.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, together with warrants to purchase up to 3,687,501 additional ADSs, at a combined purchase price of $1.20 per ADS and accompanying warrants. Under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms. A.G.P./Alliance Global Partners is serving as sole placement agent for the transactions.
Scinai plans to use the net proceeds, together with existing cash resources, to expand its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. This strategic allocation underscores the company's dual focus on providing development and manufacturing services through Scinai Biopharma Services Ltd. in Jerusalem and Yavne, Israel, while also advancing innovative immunology therapies licensed from the Max Planck Society and PinCell S.r.l.
The announcement signals potential growth for Scinai's CDMO operations, which serve biotechnology and pharmaceutical companies. By bolstering its manufacturing capabilities, Scinai aims to capture a larger share of the growing demand for contract development and manufacturing services. Simultaneously, continued investment in its immunotherapy pipeline could yield long-term value through therapeutic breakthroughs. For investors, the transaction demonstrates ongoing institutional support and provides capital to execute on both fronts without relying solely on external financing.
For more details, the full press release is available at https://ibn.fm/eUtYO. The latest news and updates relating to SCNI can be found in the company's newsroom at https://ibn.fm/SCNI. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
